A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
This is an investigator-initiated, multicenter, open-label study of C-CAR168, an autologous bi-specific CAR-T therapy targeting CD20 and BCMA, for the treatment of adult patients with autoimmune diseases refractory to standard therapy
Systemic Lupus Erythematosus (SLE)|Immune-Mediated Necrotizing Myopathy|Neuromyelitis Optica Spectrum Disorders|Multiple Sclerosis-Relapsing-Remitting|Myasthenia Gravis
BIOLOGICAL: CD20/BCMA-directed CAR-T cells
Incidence of Adverse Events [Safety and Tolerability], Incidence of any adverse events (AEs), including dose limiting toxicities (DLTs), Throughout the first 24 months follow up period completion (3 years)，DLTs will be observed/collected throughout the 28 days post C-CAR168 infusion|The subsequent recommended dose of C-CAR168 in patients with autoimmune diseases refractory to standard therapy, Based on the assessment of dose-limiting toxicities (DLTs) rates and overall safety profile, Throughout the first 24 months follow up period completion (3 years)
The proportion of subjects who achieved remission at 6 months (6M), Throughout the first 6 months follow up period completion (1.5 years)|The proportion of subjects who achieved remission during the main study period, Throughout the first 24 months follow up period completion (3 years)|The proportion of subjects who experienced relapse during the main study period, Throughout the first 24 months follow up period completion (3 years)|Time to response (TTR), The time from the date of C-CAR168 infusion to the first documented remission, Throughout the first 24 months follow up period completion (3 years)|Progression-free survival (PFS), The time from the date of C-CAR168 infusion to the date of first documented disease progression or death, whichever comes first, Throughout the first 24 months follow up period completion (3 years)|The proportion of subjects who achieved glucocorticoids/immunosuppressant free and subjects who achieved low-dose glucocorticoids application during the main study period, Throughout the first 24 months follow up period completion (3 years)|Maximal plasma concentration (Cmax), Maximal plasma concentration of C-CAR168 in peripheral blood, Throughout the first 24 months follow up period completion (3 years)|Time to reach the maximal plasma concentration (Tmax), Time to reach the maximal plasma concentration of C-CAR168 in peripheral blood, Throughout the first 24 months follow up period completion (3 years)|Duration in peripheral blood (Tlast), The duration of C-CAR168 in peripheral blood, Throughout the first 24 months follow up period completion (3 years)|Area under curve (AUC), Area under the curve of C-CAR168 in peripheral blood, Throughout the first 24 months follow up period completion (3 years)|The clearance of peripheral blood B cell, Throughout the first 24 months follow up period completion (3 years)|The decline of serum immunoglobulin, Throughout the first 24 months follow up period completion (3 years)|The elevation of peripheral blood complement, Throughout the first 24 months follow up period completion (3 years)|The decline of autoantibodies or other disease specific biomarkers, Throughout the first 24 months follow up period completion (3 years)
Serum cytokines (including Interleukin (IL)-2, IL-4, IL-6, IL-10, Tumor Necrosis Factor (TNF)-α, Interferon (IFN)-γ) changes, Detection of serum cytokines (including IL-2, IL-4, IL-6, IL-10, TNF-α, IFN-γ) changes over time by flow cytometry, Throughout the first 24 months follow up period completion (3 years)|Soluble BCMA changes in peripheral blood, Detection of soluble BCMA changes in peripheral blood by Enzyme Linked ImmunoSorbent Assay (ELISA), Throughout the first 24 months follow up period completion (3 years)|B cells changes in bone marrow, muscle or kidney, Detection of B cells concentration changes in bone marrow, muscle or kidney by flow cytometry, Throughout the first 24 months follow up period completion (3 years)|Plasma cells or long-lived plasma cells changes in bone marrow, muscle or kidney, Detection of plasma cells or long-lived plasma cells concentration changes in bone marrow, muscle or kidney by flow cytometry, Throughout the first 24 months follow up period completion (3 years)|RNA changes in peripheral blood, Detection of RNA changes in peripheral blood by RNA sequencing, Throughout the first 24 months follow up period completion (3 years)
This is an investigator-initiated, multicenter, open-label study of C-CAR168, an autologous bi-specific CAR-T therapy targeting CD20 and BCMA, for the treatment of adult patients with autoimmune diseases refractory to standard therapy